Neuronetics Q4 revenue up 12% to $20.3M; net loss narrows to $5.4M; first positive cash flow

Neuronetics, Inc.

Q4 2023 revenue $20.3M (+12% YoY); full-year revenue $71.3M (+9% YoY).
Q4 net loss $(5.4)M ($(0.19)/share) vs $(8.3)M loss a year ago; first-ever positive cash flow of $1.5M.
U.S. treatment session revenue up 20% in Q4 to $14.9M; local consumable treatment session revenue up >33%.
Full-year 2024 revenue guidance $78M-$80M; Q1 2024 guidance $16.7M-$17.7M.
Launched Better Me Guarantee Provider pilot with ~100 sites; insurers reduce TMS eligibility to 2 medication failures.

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

Neuronetics, Inc. reported three and twelve months ended December 31, 2023 results: revenue $20.3 million; $71.3 million, net income $(5.4) million; not stated for full year, EPS $(0.19) per share; not stated for full year.

Period: three and twelve months ended December 31, 2023
Revenue: $20.3 million; $71.3 million
Net income: $(5.4) million; not stated for full year
EPS: $(0.19) per share; not stated for full year
Result: reported results

Exact text from the filing

in the world, today announced its financial and operating results for the fourth quarter and full year of 2023. Fourth Quarter 2023 Highlights ● Fourth quarter 2023 revenue of $20.3 million, a 12% increase as compared to the fourth quarter 2022 ● U.S. NeuroStar Advanced Therapy system revenue of $4.5 million, in the quarter, the Company shipped 59 systems ● Achieved

View on SEC.gov

1050 earnings releases filed in the last 30 days. Browse all earnings releases →

Neuronetics, Inc. filing history →

Source: SEC EDGAR

accession 0001558370-24-002411

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.